Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis

Pachydermoperiostosis, or primary hypertrophic osteoarthropathy (PHO), is an inherited multisystem disorder, whose features closely mimic the reactive osteoarthropathy that commonly accompanies neoplastic and inflammatory pathologies. We previously described deficiency of the prostaglandin-degrading...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2012
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/24227
Acceso en línea:
https://doi.org/10.1002/humu.22111
https://repository.urosario.edu.co/handle/10336/24227
Palabra clave:
15 hydroxyprostaglandin dehydrogenase
Carrier protein
Prostaglandin e receptor 1
Prostaglandin e receptor 2
Prostaglandin e receptor 3
Prostaglandin e receptor 4
Prostaglandin e2
Slco2a1 protein
Unclassified drug
Adolescent
Adult
Article
Child
Controlled study
Ethnicity
Exome
Gene deletion
Gene mutation
Gene rearrangement
Gene sequence
Genetic association
Human
Missense mutation
Myelofibrosis
Nonsense mutation
Nucleotide sequence
Osteoarthropathy
Pachydermoperiostosis
Population genetics
Priority journal
Prostaglandin metabolism
School child
Stop codon
Adolescent
Adult
Child
Female
Genetic predisposition to disease
Humans
Male
Mutation
Organic anion transporters
Primary myelofibrosis
Prostaglandins
Young adult
Genetics
Myelofibrosis
Osteoarthropathy
Prostaglandin
Slc02a1
primary hypertrophic
Osteoarthropathy
Rights
License
Abierto (Texto Completo)
id EDOCUR2_d2181ce4c18bed5e87e886146d93a684
oai_identifier_str oai:repository.urosario.edu.co:10336/24227
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
dc.title.spa.fl_str_mv Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
title Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
spellingShingle Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
15 hydroxyprostaglandin dehydrogenase
Carrier protein
Prostaglandin e receptor 1
Prostaglandin e receptor 2
Prostaglandin e receptor 3
Prostaglandin e receptor 4
Prostaglandin e2
Slco2a1 protein
Unclassified drug
Adolescent
Adult
Article
Child
Controlled study
Ethnicity
Exome
Gene deletion
Gene mutation
Gene rearrangement
Gene sequence
Genetic association
Human
Missense mutation
Myelofibrosis
Nonsense mutation
Nucleotide sequence
Osteoarthropathy
Pachydermoperiostosis
Population genetics
Priority journal
Prostaglandin metabolism
School child
Stop codon
Adolescent
Adult
Child
Female
Genetic predisposition to disease
Humans
Male
Mutation
Organic anion transporters
Primary myelofibrosis
Prostaglandins
Young adult
Genetics
Myelofibrosis
Osteoarthropathy
Prostaglandin
Slc02a1
primary hypertrophic
Osteoarthropathy
title_short Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
title_full Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
title_fullStr Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
title_full_unstemmed Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
title_sort Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
dc.subject.keyword.spa.fl_str_mv 15 hydroxyprostaglandin dehydrogenase
Carrier protein
Prostaglandin e receptor 1
Prostaglandin e receptor 2
Prostaglandin e receptor 3
Prostaglandin e receptor 4
Prostaglandin e2
Slco2a1 protein
Unclassified drug
Adolescent
Adult
Article
Child
Controlled study
Ethnicity
Exome
Gene deletion
Gene mutation
Gene rearrangement
Gene sequence
Genetic association
Human
Missense mutation
Myelofibrosis
Nonsense mutation
Nucleotide sequence
Osteoarthropathy
Pachydermoperiostosis
Population genetics
Priority journal
Prostaglandin metabolism
School child
Stop codon
Adolescent
Adult
Child
Female
Genetic predisposition to disease
Humans
Male
Mutation
Organic anion transporters
Primary myelofibrosis
Prostaglandins
Young adult
Genetics
Myelofibrosis
Osteoarthropathy
Prostaglandin
Slc02a1
topic 15 hydroxyprostaglandin dehydrogenase
Carrier protein
Prostaglandin e receptor 1
Prostaglandin e receptor 2
Prostaglandin e receptor 3
Prostaglandin e receptor 4
Prostaglandin e2
Slco2a1 protein
Unclassified drug
Adolescent
Adult
Article
Child
Controlled study
Ethnicity
Exome
Gene deletion
Gene mutation
Gene rearrangement
Gene sequence
Genetic association
Human
Missense mutation
Myelofibrosis
Nonsense mutation
Nucleotide sequence
Osteoarthropathy
Pachydermoperiostosis
Population genetics
Priority journal
Prostaglandin metabolism
School child
Stop codon
Adolescent
Adult
Child
Female
Genetic predisposition to disease
Humans
Male
Mutation
Organic anion transporters
Primary myelofibrosis
Prostaglandins
Young adult
Genetics
Myelofibrosis
Osteoarthropathy
Prostaglandin
Slc02a1
primary hypertrophic
Osteoarthropathy
dc.subject.keyword.eng.fl_str_mv primary hypertrophic
Osteoarthropathy
description Pachydermoperiostosis, or primary hypertrophic osteoarthropathy (PHO), is an inherited multisystem disorder, whose features closely mimic the reactive osteoarthropathy that commonly accompanies neoplastic and inflammatory pathologies. We previously described deficiency of the prostaglandin-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (HPGD) as a cause of this condition, implicating elevated circulating prostaglandin E2 (PGE2) as causative of PHO, and perhaps also as the principal mediator of secondary HO. However, PHO is genetically heterogeneous. Here, we use whole-exome sequencing to identify recessive mutations of the prostaglandin transporter SLCO2A1, in individuals lacking HPGD mutations. We performed exome sequencing of four probands with severe PHO, followed by conventional mutation analysis of SLCO2A1 in nine others. Biallelic SLCO2A1 mutations were identified in 12 of the 13 families. Affected individuals had elevated urinary PGE2, but unlike HPGD-deficient patients, also excreted considerable quantities of the PGE2 metabolite, PGE-M. Clinical differences between the two groups were also identified, notably that SLCO2A1-deficient individuals have a high frequency of severe anemia due to myelofibrosis. These findings reinforce the key role of systemic or local prostaglandin excess as the stimulus to HO. They also suggest that the induction or maintenance of hematopoietic stem cells by prostaglandin may depend upon transporter activity. © 2012 Wiley Periodicals, Inc.
publishDate 2012
dc.date.created.spa.fl_str_mv 2012
dc.date.accessioned.none.fl_str_mv 2020-05-26T00:10:25Z
dc.date.available.none.fl_str_mv 2020-05-26T00:10:25Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1002/humu.22111
dc.identifier.issn.none.fl_str_mv 10981004
10597794
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/24227
url https://doi.org/10.1002/humu.22111
https://repository.urosario.edu.co/handle/10336/24227
identifier_str_mv 10981004
10597794
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 1181
dc.relation.citationIssue.none.fl_str_mv No. 8
dc.relation.citationStartPage.none.fl_str_mv 1175
dc.relation.citationTitle.none.fl_str_mv Human Mutation
dc.relation.citationVolume.none.fl_str_mv Vol. 33
dc.relation.ispartof.spa.fl_str_mv Human Mutation, ISSN:10981004, 10597794, Vol.33, No.8 (2012); pp. 1175-1181
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863859795&doi=10.1002%2fhumu.22111&partnerID=40&md5=cb9d6974f7502abe963c1693be4e5cce
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167630071726080
spelling 282a8aa6-ab94-41fd-a183-7b6cff66f4eff2d4f4e1-3e20-464a-81b1-ef45777b5f0b796d0c71-a74f-45a5-88cb-5ac134b54c617978277070b0e4ad-dd22-4cd7-936d-9699bfad86fd52094825600b4e0d7d9-6608-4224-8764-2c2015081bef4ca4788b-1eca-4b8f-884a-f2237909cd432c505359-a84e-4f52-a623-7693dd229188dfd7fe1e-f1d1-4534-ba50-55d432acfae9f1546e53-837d-4cdc-80d9-69c31e7d77b9de9160a1-1e90-455d-a8fb-853139e1a1fa4a634df8-4d51-45c6-acd6-76682448d8aff0a592ee-d0ac-4323-9785-f8f8b4f683341ba20053-167b-416d-a266-17b6ca7077e40e930d5f-4308-47cb-9379-4155a3f7efbcfc32d029-eb72-48f8-a929-0930876d7a931ff6bb07-1472-4b7d-baca-53b556dd026c8f82dc3f-8fdf-4e43-875c-8bbde80e8b4e33316bd6-2df0-42ae-a006-76fb0355d14ffcf6cb69-5f5e-44fe-88cd-831007180ea67b6e1ad6-74cf-48fb-9d02-bc54f6c845415d03e238-2428-4d52-b456-7a14382fa4f20131128d-a7c2-4b9d-8679-03a4479c438cb627daea-d755-4145-9492-c5089ef6f59252ead79f-bc79-4ec1-bc5d-a4b518a50387f285b2d2-e991-4ad2-a593-16771731daedb43213a8-59e2-4a95-9a33-2f70014f7e0bd7035146-159f-4ab4-8b23-16c9fa5e574b2d23f5db-bd6c-4464-96d8-6d5ecc1844263c9f9628-f012-472c-a9a9-5adb88eddb2ec5197225-fe38-409e-9bee-17b0da47f6b88023bb04-dfe7-40d8-911c-29392c934e09193318196002020-05-26T00:10:25Z2020-05-26T00:10:25Z2012Pachydermoperiostosis, or primary hypertrophic osteoarthropathy (PHO), is an inherited multisystem disorder, whose features closely mimic the reactive osteoarthropathy that commonly accompanies neoplastic and inflammatory pathologies. We previously described deficiency of the prostaglandin-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (HPGD) as a cause of this condition, implicating elevated circulating prostaglandin E2 (PGE2) as causative of PHO, and perhaps also as the principal mediator of secondary HO. However, PHO is genetically heterogeneous. Here, we use whole-exome sequencing to identify recessive mutations of the prostaglandin transporter SLCO2A1, in individuals lacking HPGD mutations. We performed exome sequencing of four probands with severe PHO, followed by conventional mutation analysis of SLCO2A1 in nine others. Biallelic SLCO2A1 mutations were identified in 12 of the 13 families. Affected individuals had elevated urinary PGE2, but unlike HPGD-deficient patients, also excreted considerable quantities of the PGE2 metabolite, PGE-M. Clinical differences between the two groups were also identified, notably that SLCO2A1-deficient individuals have a high frequency of severe anemia due to myelofibrosis. These findings reinforce the key role of systemic or local prostaglandin excess as the stimulus to HO. They also suggest that the induction or maintenance of hematopoietic stem cells by prostaglandin may depend upon transporter activity. © 2012 Wiley Periodicals, Inc.application/pdfhttps://doi.org/10.1002/humu.221111098100410597794https://repository.urosario.edu.co/handle/10336/24227eng1181No. 81175Human MutationVol. 33Human Mutation, ISSN:10981004, 10597794, Vol.33, No.8 (2012); pp. 1175-1181https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863859795&doi=10.1002%2fhumu.22111&partnerID=40&md5=cb9d6974f7502abe963c1693be4e5cceAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocUR15 hydroxyprostaglandin dehydrogenaseCarrier proteinProstaglandin e receptor 1Prostaglandin e receptor 2Prostaglandin e receptor 3Prostaglandin e receptor 4Prostaglandin e2Slco2a1 proteinUnclassified drugAdolescentAdultArticleChildControlled studyEthnicityExomeGene deletionGene mutationGene rearrangementGene sequenceGenetic associationHumanMissense mutationMyelofibrosisNonsense mutationNucleotide sequenceOsteoarthropathyPachydermoperiostosisPopulation geneticsPriority journalProstaglandin metabolismSchool childStop codonAdolescentAdultChildFemaleGenetic predisposition to diseaseHumansMaleMutationOrganic anion transportersPrimary myelofibrosisProstaglandinsYoung adultGeneticsMyelofibrosisOsteoarthropathyProstaglandinSlc02a1primary hypertrophicOsteoarthropathyProstaglandin transporter mutations cause pachydermoperiostosis with myelofibrosisarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Diggle, Christine P.Parry, David A.Logan, Clare V.Laissue, PaulRivera, CarolinaFonseca Mendoza, Dora JanethMorgan, Joanne E.Allanore, YannickFontenay, MichaelaWipff, JulienVarret, MathildeGibault, LaureDalantaeva, NadezhdaKorbonits, MártaZhou, BowenYuan, GangHarifi, GhitaCefle, KivancPalanduz, SukruAkoglu, HadimZwijnenburg, Petra J.Lichtenbelt, Klaske D.Aubry?Rozier, BérengèreSuperti?Furga, AndreaDallapiccola, BrunoAccadia, MariaBrancati, FrancescoSheridan, Eamonn G.Taylor, Graham R.Carr, Ian M.Johnson, Colin A.Markham, Alexander F.Bonthron, David T.Restrepo Fernández, Carlos Martín10336/24227oai:repository.urosario.edu.co:10336/242272022-05-02 07:37:16.113324https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co